In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

PS makes wellness more accessible through real-life stories, first-person perspectives, and expert-backed information. Our ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...